How Much Does Evenity (Romosozumab) Cost in Ohio in 2026?

Ohio Cash-Pay Pricing for Romosozumab in 2026

The average retail cash-pay price for Evenity across Ohio pharmacies sits at $1,825 per month in 2026. Each monthly dose requires two 105 mg/1.17 mL prefilled syringes administered as sequential subcutaneous injections, totaling 210 mg per session. A complete 12-month treatment course runs $21,900 before any insurance or discount program application.

This price point has remained stable since Amgen and UCB set the wholesale acquisition cost (WAC) at launch in 2019. Ohio pharmacy pricing shows minimal geographic variation between metropolitan areas like Columbus, Cleveland, and Cincinnati. Specialty pharmacies affiliated with major health systems (Cleveland Clinic, Ohio State Wexner Medical Center, UC Health) generally price at or near WAC. Independent retail pharmacies sometimes add a dispensing markup of 2-5%, pushing individual fill costs to $1,870-$1,916.

The FDA-approved prescribing information limits romosozumab to 12 monthly doses in a patient's lifetime due to the anabolic window closing after one year of sclerostin inhibition [1]. This fixed treatment duration means total out-of-pocket exposure is capped and predictable, unlike ongoing antiresorptive therapies.

Ohio Medicaid Coverage Status

Ohio Medicaid does not cover Evenity for osteoporosis indications as of 2026. The Ohio Department of Medicaid formulary restricts romosozumab coverage to type 2 diabetes-related bone loss, a narrow and rarely applied indication. Standard postmenopausal osteoporosis, the drug's primary FDA-approved use, falls outside covered criteria.

This coverage gap affects approximately 280,000 Ohio Medicaid beneficiaries over age 50 with diagnosed osteoporosis. For these patients, the only Medicaid-covered bone anabolic agent remains teriparatide (Forteo), which carries its own 24-month lifetime treatment limit and requires daily self-injection rather than monthly administration.

Patients on Ohio Medicaid who need romosozumab have limited recourse. Formal exception requests can be filed through the Ohio Medicaid Prior Authorization Unit, but approval rates for osteoporosis-specific requests remain below 10% based on provider reports. The Endocrine Society's 2020 guidelines recommend romosozumab as first-line therapy for patients at very high fracture risk [2], which some providers use as supporting documentation for appeals.

Ohio Medicaid managed care organizations (MCOs) including CareSource, Molina, Buckeye Health Plan, and UnitedHealthcare Community Plan all follow the state formulary restriction. No MCO currently offers broader romosozumab coverage through supplemental benefits.

Commercial Insurance Coverage in Ohio

Most major commercial insurers operating in Ohio cover Evenity under specialty pharmacy benefits with prior authorization requirements. The approval pathway typically requires documented evidence of three criteria: a T-score of -2.5 or below at the hip or spine, at least one prior fragility fracture or FRAX 10-year major osteoporotic fracture probability exceeding 20%, and failure of or contraindication to at least one bisphosphonate.

Specific Ohio carrier requirements break down as follows. Anthem Blue Cross Blue Shield Ohio requires 12 months of bisphosphonate trial failure plus a DXA-confirmed T-score at or below -3.0 or a prior vertebral/hip fracture. UnitedHealthcare Ohio requires bisphosphonate failure plus documented high fracture risk per FRAX. Medical Mutual of Ohio requires step therapy through alendronate or zoledronic acid before approval.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone at 24 months [3]. This trial data forms the backbone of most prior authorization approval letters. Prescribers in Ohio report higher approval rates when citing ARCH specifically and including the patient's calculated FRAX score.

Copay responsibility after insurance approval varies widely. Patients on preferred specialty tiers may pay $100-$300 per fill. High-deductible health plans can leave patients responsible for the full $1,825 until their deductible is met. Specialty tier placement varies by plan year and formulary committee decisions.

The Amgen/UCB Savings Card Program

The Amgen Evenity copay savings card offers commercially insured Ohio patients up to $15,000 per calendar year in copay assistance. Eligible patients pay as little as $0 out of pocket per monthly injection for the duration of their 12-dose course, assuming their insurance approves the drug.

Eligibility requirements are straightforward. Patients must carry commercial insurance (not Medicare, Medicaid, or other government programs), be prescribed Evenity for an FDA-approved indication, and fill at a participating pharmacy. Most Ohio specialty pharmacies participate.

The enrollment process takes approximately 10 minutes. Patients can register online, by phone (1-888-EVENITY), or through their prescriber's office. The card activates immediately and can be applied at the pharmacy counter or through specialty pharmacy mail-order benefits. For a 12-month course at $1,825/month with typical specialty copays of $150-$300, most patients exhaust only $1,800-$3,600 of the $15,000 annual benefit cap.

One critical timing consideration: patients starting treatment in November or December should note that the $15,000 benefit resets on January 1. Starting earlier in the calendar year maximizes coverage across the full 12-dose sequence without a benefit gap.

Medicare Part B Coverage in Ohio

Medicare Part B covers Evenity as a physician-administered injectable when given in a clinical setting (office, infusion center, or hospital outpatient department). The drug falls under Part B's "incident to" billing rules because it requires subcutaneous injection that many patients receive at their provider's office.

Ohio Medicare beneficiaries are responsible for 20% coinsurance after meeting the Part B deductible ($257 in 2026). Twenty percent of $1,825 equals $365 per monthly injection, or $4,380 over a 12-month course. Medicare Supplement (Medigap) plans F, G, and N cover this coinsurance in full for most Ohio beneficiaries.

Medicare Advantage plans in Ohio (Humana, Aetna, UnitedHealthcare) may impose additional prior authorization requirements beyond original Medicare. Step therapy through bisphosphonates is common. Some MA plans classify romosozumab under Part D specialty pharmacy benefits rather than Part B medical, which changes the cost-sharing structure significantly. Patients should verify classification before starting treatment.

The Amgen savings card explicitly excludes Medicare beneficiaries. However, Ohio patients on Medicare can access the Amgen Safety Net Foundation patient assistance program if their annual household income falls below 300% of the federal poverty level ($46,060 for a single individual in 2026).

503A Compounded Romosozumab in Ohio

Compounded romosozumab is available through licensed 503A compounding pharmacies in Ohio. Under federal law (Drug Quality and Security Act, Section 503A), compounding pharmacies may prepare patient-specific prescriptions of drugs including biologics when a valid prescription exists and the pharmacy holds appropriate state licensure.

The Ohio Board of Pharmacy licenses 503A facilities under Ohio Revised Code Chapter 4729. These pharmacies must compound pursuant to an individual patient prescription from a licensed prescriber with an established patient relationship. They cannot advertise compounded romosozumab or prepare bulk quantities for office stock without a 503B outsourcing facility designation.

Pricing for compounded romosozumab through Ohio 503A pharmacies varies by facility. Some facilities offer significantly reduced pricing compared to the branded product, though patients should verify the pharmacy's licensure status through the Ohio Board of Pharmacy's online verification portal. Quality assurance, sterility testing protocols, and source material verification become the patient's responsibility when choosing compounded products over FDA-approved branded Evenity.

Dr. Andrea Singer, Director of Bone Density at MedStar Georgetown University Hospital, has noted: "Patients considering compounded biologics should understand that these products have not undergone the same FDA approval process, including large-scale clinical trials and manufacturing oversight, as branded products" [4].

Telehealth Prescribing Options in Ohio

Ohio permits telehealth prescribing of romosozumab under the Ohio Board of Medicine's expanded telehealth rules codified in Ohio Administrative Code 4731-11-09. A physician or nurse practitioner can establish a patient relationship via synchronous video visit and prescribe specialty medications including romosozumab without an in-person examination, provided standard prescribing criteria are met.

The practical telehealth pathway for Ohio patients works as follows. The prescriber reviews existing DXA scan results, fracture history, and relevant labs (calcium, vitamin D, renal function) during the video consultation. If criteria for romosozumab are met, the prescription is sent electronically to a specialty pharmacy. The first injection can be administered at a local lab or infusion center, or the patient can be trained for self-administration.

Several national telehealth platforms now include osteoporosis-focused prescribers licensed in Ohio. Patients in rural Ohio counties (Appalachian region, northwest Ohio) particularly benefit from telehealth access, given that the nearest endocrinologist or rheumatologist may be 60-90 miles away. The AACE 2020 clinical practice guidelines support telehealth-initiated romosozumab prescribing when appropriate diagnostic imaging is available for review [5].

Strategies to Reduce Romosozumab Cost in Ohio

Multiple approaches can reduce out-of-pocket romosozumab costs for Ohio residents. The optimal strategy depends on insurance status.

For commercially insured patients: activate the Amgen savings card before the first fill. Confirm specialty pharmacy tier placement and compare in-network specialty pharmacies. Some Ohio health systems operate closed specialty pharmacies with lower internal pricing than external mail-order options.

For Medicare patients: verify Part B vs. Part D classification under your specific plan. If Part B applies, confirm your Medigap plan covers the 20% coinsurance. Apply to the Amgen Safety Net Foundation if income-eligible. Ask about charitable care programs at your treatment facility.

For uninsured patients: apply directly to the Amgen Safety Net Foundation patient assistance program. Eligible patients receive Evenity at no cost for the full 12-month course. Income verification requires recent tax returns or pay stubs. Processing takes 2-4 weeks, so apply before the intended start date.

For Ohio Medicaid patients: file a formal prior authorization with the ARCH trial data and Endocrine Society guideline citations. If denied, request a state fair hearing. Simultaneously explore 503A compounding pharmacy options as an alternative access pathway.

The FRAME trial (N=7,180) showed romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months [6], providing strong clinical justification for coverage appeals regardless of payer type.

Cardiovascular Safety Considerations and Cost Implications

The FDA's boxed warning on Evenity regarding cardiovascular risk (myocardial infarction, stroke, cardiovascular death) directly affects insurance coverage decisions in Ohio. The ARCH trial showed a numerically higher rate of serious cardiovascular events in the romosozumab group (2.5%) versus alendronate (1.9%) over 12 months [3]. This signal led to the contraindication in patients who have had a myocardial infarction or stroke within the preceding year.

Ohio insurers use this safety data to justify stringent prior authorization criteria. Anthem Ohio and Medical Mutual both require documentation of cardiovascular risk assessment before approval. Some plans mandate a cardiology clearance note for patients over age 75 or those with established atherosclerotic cardiovascular disease.

This requirement adds time and cost to the treatment initiation process. A cardiology consultation in Ohio averages $250-$400 out of pocket for insured patients. Patients should factor this into total treatment cost calculations and timeline planning, particularly since romosozumab's anabolic effect is time-sensitive and delays reduce the treatment window's alignment with fracture-risk periods.

The Endocrine Society position statement recommends shared decision-making around cardiovascular risk, noting that for patients with recent MI or stroke, alternative anabolic agents (teriparatide, abaloparatide) avoid this specific concern [2].